The Impact of Noradrenaline on Ventriculo-arterial Coupling and Central Cardiovascular Energy Delivery
Primary Purpose
Heart Diseases
Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Noradrenalin
Noradrenalin
Noradrenalin
Noradrenalin
Sponsored by

About this trial
This is an interventional basic science trial for Heart Diseases focused on measuring Noradrenaline, Heart surgery, Intensive care, Cardiac physiology
Eligibility Criteria
Inclusion Criteria:
- elective coronary artery bypass graft surgery
- requirement for Noradrenaline/Norepinephrine
Exclusion Criteria:
- lack of informed consent
- patient unsuitable for mean arterial pressure (MAP) elevation of 20mmHg
- patient requiring different blood pressure range due to medical/surgical needs
- poor image quality due to patient factors
Sites / Locations
- St Olavs Hospital, Dep. for Anesthesia & Intensive care. Section of cardiothoracic Anesthesia and -intensive Care.
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Noradrenalin
Arm Description
treatment with 2 different NA concentrations in 2 different states of fluid responsiveness
Outcomes
Primary Outcome Measures
Change in Cardiac Power
Change in Cardiac Power in reaction to both different noradrenaline doses and states of fluid responsiveness.
By logging invasive BP curve and tracing left ventricular outflow tract Velocity Time Integral (by echocardiography) simultaneously Total and Mean Cardiac Power (Watt) can be determined. Examining the response to different NA doses relative to fluid responsiveness the effect of NA on arterio-ventricular coupling can be examined.
Change in Oscillatory Power Fraction
Change in Oscillatory Power Fraction (OPF) in reaction to both different noradrenaline doses and states of fluid responsiveness.
By logging invasive BP curve and tracing left ventricular outflow tract Velocity Time Integral (by echocardiography) simultaneously Total Cardiac Power (TCP, Watt) and Cardiac Power Output (CPO, Watt) can be determined. By subtracting CPO from TCP, OPF (in %) can be calculated. Examining the response to different NA doses relative to fluid responsiveness the effect of NA on arterio-ventricular coupling can be examined.
Secondary Outcome Measures
Change in single beat ventricular elastance
Change in single beat ventricular elastance in reaction to both different noradrenaline doses and states of fluid responsiveness.
Ventricular elastance (Ees) can be determined on the bedside by using a single beat measurement of left ventricular ejection fraction, stroke volume, preejection time and ejection time.
Change in single beat arterial elastance
Change in single beat arterial elastance in reaction to both different noradrenaline doses and states of fluid responsiveness. Using an estimative formula Ea can be calculated (Ea=SBPx0.9/SV) and Ea/Ees as a marker of arterio-ventricular coupling can be evaluated.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04745845
Brief Title
The Impact of Noradrenaline on Ventriculo-arterial Coupling and Central Cardiovascular Energy Delivery
Official Title
The Impact of Noradrenaline on Ventriculo-arterial Coupling and Central Cardiovascular Energy Delivery
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
March 1, 2021 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
December 31, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
St. Olavs Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study aims to examine how noradrenaline in combination with venous return influences the energy transmission from heart to central circulation and arteries - also called arterio-ventricular coupling.
Detailed Description
After being informed about the study 40 elective CABG patients with written informed consent will undergo assessment of their arterio-ventricular coupling postoperatively after coronary bypass graft surgery. Whilst still in deep general anesthesia on the CT ICU the study population will be assessed by echocardiographic examination (transthoracic and transesophageal), blood pressure tracing by arterial line, respiratory data and ECG in 4 different situations.
Initially the individual patient is either considered fluid responsive (SVV >13%) og non- responsive (SVV<13%) by using stroke volume variation assessed by echocardiography.
In case of fluid responsiveness a fluid bolus of 4ml/kg of crystalloid fluid is given until SVV drops below 13% and the patient can be considered as fluid NON responder.
Right afterwards the study patient is stabilized with a baseline dose of noradrenaline (NA) intravenously in a supine position (situation 1). Situation 2 will be a slight increase in NA dose stabilizing mean arterial pressure in a "baseline + 20mmHg" state. After reversing the NA dose back to base line level the patient is allowed a short period of rest to wean of drug effect (4-5 x t1/2, appr. 12min). Subsequently the patient is to be placed in a 20% semi upright position (Anti-Trendelenburg) causing an increase in fluid responsiveness (situation 3). Following a phase of equilibration the dose of NA is again titrated up to obtain a 20mmHg increase in mean arterial pressure (situation 4).
There will be logging of arterial pressure curve and VTI-tracing I LVOT simultaneously (ultrapower, uPWR) as well as calculation of energy delivery, cardiac power, oscillatory power and -fraction and both arterial and ventricular elastance in every of those 4 situations.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Diseases
Keywords
Noradrenaline, Heart surgery, Intensive care, Cardiac physiology
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
49 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Noradrenalin
Arm Type
Experimental
Arm Description
treatment with 2 different NA concentrations in 2 different states of fluid responsiveness
Intervention Type
Procedure
Intervention Name(s)
Noradrenalin
Other Intervention Name(s)
Anti-Trendelenburg position/Semiupright position (20degr)
Intervention Description
Norepinephrine challenge (concentration 'A' ) in fluid responsive position
Intervention Type
Procedure
Intervention Name(s)
Noradrenalin
Other Intervention Name(s)
supine position
Intervention Description
Norepinephrine challenge (concentration 'A') in non-fluid responsive position
Intervention Type
Procedure
Intervention Name(s)
Noradrenalin
Other Intervention Name(s)
Anti-Trendelenburg position/Semiupright position (20degr)
Intervention Description
Norepinephrine challenge (concentration 'B') in fluid responsive position
Intervention Type
Procedure
Intervention Name(s)
Noradrenalin
Other Intervention Name(s)
supine position
Intervention Description
Norepinephrine challenge (concentration 'B') in non-fluid responsive position
Primary Outcome Measure Information:
Title
Change in Cardiac Power
Description
Change in Cardiac Power in reaction to both different noradrenaline doses and states of fluid responsiveness.
By logging invasive BP curve and tracing left ventricular outflow tract Velocity Time Integral (by echocardiography) simultaneously Total and Mean Cardiac Power (Watt) can be determined. Examining the response to different NA doses relative to fluid responsiveness the effect of NA on arterio-ventricular coupling can be examined.
Time Frame
within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
Title
Change in Oscillatory Power Fraction
Description
Change in Oscillatory Power Fraction (OPF) in reaction to both different noradrenaline doses and states of fluid responsiveness.
By logging invasive BP curve and tracing left ventricular outflow tract Velocity Time Integral (by echocardiography) simultaneously Total Cardiac Power (TCP, Watt) and Cardiac Power Output (CPO, Watt) can be determined. By subtracting CPO from TCP, OPF (in %) can be calculated. Examining the response to different NA doses relative to fluid responsiveness the effect of NA on arterio-ventricular coupling can be examined.
Time Frame
within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
Secondary Outcome Measure Information:
Title
Change in single beat ventricular elastance
Description
Change in single beat ventricular elastance in reaction to both different noradrenaline doses and states of fluid responsiveness.
Ventricular elastance (Ees) can be determined on the bedside by using a single beat measurement of left ventricular ejection fraction, stroke volume, preejection time and ejection time.
Time Frame
within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
Title
Change in single beat arterial elastance
Description
Change in single beat arterial elastance in reaction to both different noradrenaline doses and states of fluid responsiveness. Using an estimative formula Ea can be calculated (Ea=SBPx0.9/SV) and Ea/Ees as a marker of arterio-ventricular coupling can be evaluated.
Time Frame
within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
elective coronary artery bypass graft surgery
requirement for Noradrenaline/Norepinephrine
Exclusion Criteria:
lack of informed consent
patient unsuitable for mean arterial pressure (MAP) elevation of 20mmHg
patient requiring different blood pressure range due to medical/surgical needs
poor image quality due to patient factors
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hilde Pleym (Head of Department), md, PhD
Organizational Affiliation
St. Olavs Hospital
Official's Role
Study Director
Facility Information:
Facility Name
St Olavs Hospital, Dep. for Anesthesia & Intensive care. Section of cardiothoracic Anesthesia and -intensive Care.
City
Trondheim
ZIP/Postal Code
7006
Country
Norway
12. IPD Sharing Statement
Learn more about this trial
The Impact of Noradrenaline on Ventriculo-arterial Coupling and Central Cardiovascular Energy Delivery
We'll reach out to this number within 24 hrs